New York, April 20, 2026, 13:32 EDT
- Pfizer and Astellas secured priority review status from the FDA for their Padcev submission in muscle-invasive bladder cancer, locking in an Aug. 17 decision deadline.
- Pfizer is set to release its first-quarter numbers on May 5, as investors look to see if its cancer and obesity lines can offset weaker COVID sales and fading exclusivity on legacy drugs.
Pfizer picked up a new short-term catalyst Monday, with the U.S. Food and Drug Administration handing a priority review to its Padcev submission for bladder cancer. The stock gained roughly 0.8%, trading at $27.78 in the afternoon, drawing renewed attention as the company pushes ahead with a wider pipeline.
The timing is key: Pfizer is set to post first-quarter results on May 5. Investors will be watching to see how the company tracks against its 2026 revenue guidance—$59.5 billion to $62.5 billion, with COVID products expected to bring in around $5 billion. That forecast already factors in an estimated $1.5 billion impact from loss of exclusivity as older drugs go off patent and generics move in. Pfizer, for its part, has said it plans to run about 20 pivotal studies that could help secure approvals before year-end.
The divide’s made its way into analyst chatter, too. Simply Wall St pointed out Pfizer’s $4.4 billion COVID write-down and shaky dividend coverage; on the other hand, writers at Seeking Alpha and Motley Fool have suggested the company’s late-stage pipeline and cheap shares might yet help revive the stock, just on a slower track as the decade moves on.
Monday’s filing offers investors a clearer benchmark. Pfizer and Astellas are aiming to widen use of Padcev plus Keytruda, taking it beyond patients ineligible for cisplatin to cover all muscle-invasive bladder cancer cases. That push comes on the back of late-stage results: a 47% reduction in recurrence, progression or death, along with a 35% lower risk of death compared to chemo. Chief Oncology Officer Jeff Legos called the treatment a potential “meaningful” shift if regulators sign off. The FDA has put an Aug. 17 decision on the calendar. Pfizer
Obesity remains the bigger challenge. Pfizer has zeroed in on GLP-1 medicines—these mimic gut hormones to suppress appetite and reduce blood sugar—building on last year’s Metsera acquisition. In February, the company reported that its once-monthly injectable, PF-3944, prompted up to 12.3% weight loss over 28 weeks in patients without diabetes. Reuters has the company eyeing its first obesity indication for 2028.
Plenty of contenders are piling in. Eli Lilly and Novo Nordisk still lead the obesity drug pack, and Reuters noted earlier this month that analysts expect sector sales could hit $150 billion a year within a decade. Kailera surged in its Nasdaq debut on Friday. IPOX Research’s Lukas Muehlbauer called obesity “one of the few areas in biotech with clear investor appetite.” Reuters
Pfizer is pushing ahead on the commercial front, too. In March, China cleared Xianweiying—its once-weekly GLP-1 therapy—for long-term weight management, marking a win for the drugmaker and putting a product on the market there. Its primary U.S. obesity drugs are still tied up in clinical trials.
Still, there are risks in the reset. Pfizer dropped its oral obesity candidate danuglipron last year, citing a possible drug-induced liver injury. When PF-3944 data landed in February, tolerability was still a sticking point—Gabelli Funds’ Daniel Barasa called the showing “good, but not category-defining.” Over at Aptus Capital Advisors, David Wagner wondered if Pfizer’s dealmaking would actually deliver “sizeable returns.” Reuters
COVID isn’t the shield it used to be. Pfizer and BioNTech earlier this month pulled the plug on a major U.S. trial testing their updated COVID vaccine in adults 50 to 64, citing sluggish recruitment—another reminder of just how much demand and the rules of the game have shifted from the peak pandemic days.
Investors have a stock here priced at roughly 13.7 times earnings, throwing off a 6.2% yield — that’s based on Pfizer’s share price and its $0.43 quarterly dividend. But the company’s pipeline has to prove it can handle the looming wave of patent expirations and the threat from generics. Next key update: May 5.
